Kathryn Feisal, PA
Physician Assistant · Oklahoma City, OKNPI 1255673349
Payments from drug & device makers
Across 192 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$688
- Boston Scientific$284
- Sumitomo Pharma America, Inc.$261
- Johnson & Johnson$234
- Rochester Medical Corporation$203
- Axonics, Inc.$201
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,80294%
- Education$2586%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 34 | $688 |
| Boston Scientific | 12 | $284 |
| Sumitomo Pharma America, Inc. | 14 | $261 |
| Johnson & Johnson | 8 | $234 |
| Rochester Medical Corporation | 9 | $203 |
| Axonics, Inc. | 5 | $201 |
| Medtronic | 11 | $199 |
| Antares Pharma, Inc. | 9 | $168 |
| Urovant Sciences Inc | 9 | $166 |
| Teleflex LLC | 8 | $158 |
| Myovant Sciences Inc. | 8 | $152 |
| Pfizer | 6 | $132 |
| Coloplast | 6 | $128 |
| Progenics Pharmaceuticals, Inc. | 5 | $108 |
| Urogen Pharma, Inc. | 5 | $106 |
| AbbVie | 6 | $103 |
| Endo Pharmaceuticals Inc. | 6 | $97 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $78 |
| Merck | 4 | $69 |
| Clarus Therapeutics Inc. | 3 | $62 |
| Novartis | 2 | $62 |
| Sagent Pharmaceuticals | 2 | $49 |
| Procept Biorobotics Corporation | 2 | $42 |
| Tolmar Pharmaceuticals, Inc. | 2 | $42 |
| Myriad Genetic Laboratories, Inc. | 2 | $41 |
| Tolmar, Inc. | 2 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $26 |
| Travere Therapeutics, Inc. | 1 | $22 |
| Endo USA, Inc. | 1 | $22 |
| Convatec Inc. | 1 | $21 |
| Vertex | 1 | $20 |
| Blue Earth Diagnostics | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $18 |
| Immunitybio, Inc. | 1 | $17 |
| Civco Medical Instruments | 1 | $16 |
| Olympus America Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,060 in reported general payments places this provider in the 90th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 248 | $190,135 |
| GemtesaVibegron | 229 | $159,872 |
| ElmironPentosan Polysulfate Sodium | 13 | $12,405 |
| Silodosin | 114 | $11,601 |
| Finasteride | 679 | $11,438 |
| Tamsulosin Hcl | 698 | $10,715 |
| PremarinEstrogens, Conjugated | 20 | $8,536 |
| Trospium Chloride ErTrospium Chloride | 41 | $6,958 |
| Trospium Chloride | 70 | $4,009 |
| Estradiol | 55 | $3,345 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 70 | $2,712 |
| Methenamine Hippurate | 26 | $2,501 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $1,846 |
| Dutasteride | 29 | $1,450 |
| Tadalafil | 13 | $1,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $688 | $190,135248 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $261 | $159,872229 claims |
| PfizerPremarin | $132 | $8,53620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Oklahoma City
- Jennifer SmithOklahoma City$134K
- Sarah HawkOklahoma City$23K
- Brooke CromerOklahoma City$14K
- Mary Jane RorickOklahoma City$14K
- Alma HintzeOklahoma City$14K
- Emily McLainOklahoma City$13K
- Deniz AktasOklahoma City$13K
- Jovonne SmithOklahoma City$12K
- Anthony SharpOklahoma City$11K
- Whitney PriceOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.